The purpose of this review is to compare the clinical effectiveness and cost-effectiveness of imiquimod (IMQ) compared to other treatment modalities for the treatment of genital warts (GW). This report is the third in the series of three reports on IMQ. The previous two reports were on IMQ for the treatment of basal cell and squamous carcinoma, and actinic keratosis.
Copyright © 2017 Canadian Agency for Drugs and Technologies in Health.